Finpecia

Basic Finpecia Information

• INN (International Nonproprietary Name): Finasteride
• Brand Names Available In United Kingdom: Propecia (1 mg), Proscar (5 mg) and various generics
• ATC Code: D11AX10 (alopecia); G04CB01 (BPH)
• Forms & Dosages: 1 mg tablet for male pattern hair loss; 5 mg tablet for benign prostatic hyperplasia
• Manufacturers In United Kingdom: not specified
• Registration Status In United Kingdom: MHRA‑licensed for Propecia 1 mg and Proscar 5 mg; generics available
• OTC / Rx Classification: Prescription Only (Rx)

Critical Warnings, Restrictions And Patient Protection

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Key UK safety points first:

Finasteride is prescription only and absolutely contraindicated in women who are, or may be, pregnant because of risk to a male foetus.

Do not handle crushed or broken tablets if pregnant.

Use extreme caution in patients with significant hepatic impairment and in those with prior hypersensitivity.

• Pregnancy — absolute contra‑indication; risk to male foetus if handled or ingested by pregnant women.
• Women/Children — not indicated and should not use finasteride.
• Known allergy to finasteride or tablet excipients.
• Severe liver disease — use with caution; finasteride is hepatically metabolised.
• Prior sexual dysfunction — discuss baseline sexual function and monitor.
• Active depression or mood disorder — assess and monitor; report changes promptly.

Interaction With Activities (Driving, Workplace Safety Under UK Law)

Most people can drive and work normally while taking finasteride.

Counsel patients to be alert for dizziness or mood change that could affect driving or machinery operation.

• Stop driving or operating machinery if you experience dizziness or syncope.
• Stop and seek medical review for severe mood change or sudden impairment.
• Record any incidents and consider reporting via the MHRA Yellow Card scheme.

Q&A — “Can I Drive After Taking It In The UK?”

Short answer: normally yes.

Stop driving and seek advice if you experience any of the following:

• Dizziness or light‑headedness.
• Syncope or fainting.
• Marked mood change or sudden confusion that affects concentration.

Usage Basics (INN, Brand Names Available In The UK; Legal Classification)

INN, Brand Names And Formulations

INN: Finasteride.

ATC codes: D11AX10 for androgenetic alopecia and G04CB01 for benign prostatic hyperplasia.

In the UK market Propecia (1 mg) and Proscar (5 mg) are licensed, alongside multiple generics.

Legal Classification (POM, P, GSL)

Finasteride is Prescription Only (POM) in the UK.

Both 1 mg and 5 mg formulations are MHRA‑licensed as prescription medicines.

POM

Prescription Only Medicine.

MHRA

Medicines and Healthcare products Regulatory Agency.

Dosing Guide (Standard Regimens And Adjustments)

Standard Regimens (NHS Context)

For male pattern hair loss the usual dose is 1 mg orally once daily.

For benign prostatic hyperplasia the standard dose is 5 mg orally once daily.

Hair‑loss benefit typically appears after three months or more and requires continuous use to maintain effect.

Adjustments For Comorbidities

No routine renal adjustment is required for most patients.

Use caution in hepatic impairment because finasteride is metabolised in the liver; severe hepatic dysfunction is a reason for extra caution or avoidance.

Elderly patients do not usually require dose changes but deserve closer monitoring for adverse events.

• Baseline PSA if relevant to urological assessment.
• Document sexual history before starting.
• Mental‑health screen for depression or mood disorders.
• Review liver function if risk factors are present.

Q&A — “What If I Miss A Dose?”

Take the missed dose as soon as you remember the same day.

Do not take a double dose the next day to make up for a missed one.

If more than 24 hours have passed, resume your normal schedule the following day.

• If unsure, skip the missed tablet and continue as usual the next day.
• Contact pharmacist or prescriber for repeated missed doses or adherence concerns.

Interaction Chart (Food, Drink, Drug Conflicts)

Food And Drink Interactions

No clinically significant food interactions have been recorded with finasteride.

Alcohol does not alter finasteride pharmacodynamics, but counsel moderation for general health and BPH symptoms.

Caffeine and tea do not affect finasteride absorption.

Common Drug Conflicts And Reporting

There are few direct pharmacokinetic drug–drug interactions with finasteride.

Use caution when combining with other 5α‑reductase inhibitors and with medicines that affect libido or mood.

• Report suspected interactions or adverse reactions via the MHRA Yellow Card scheme.

User Reports & Trends (NHS Choices, Patient.info, Mumsnet Insights)

People visiting forums and patient sites frequently ask how quickly hair improves and whether sexual or mood adverse events are permanent.

Common patient narratives praise hair stabilisation and modest regrowth over months, while harms reported most often relate to sexual function and mood.

• Reported benefits: halting hair loss, increased hair density, slowed progression.
• Reported harms: decreased libido, erectile dysfunction, ejaculatory changes, mood disturbance.

“Post‑finasteride syndrome” appears in patient narratives and remains under scientific review; clinicians should take reports seriously and document findings.

Clinicians should triangulate forum trends with MHRA Yellow Card reports and published literature, avoid dismissing symptoms and offer review or referral.

Access & Purchase Options (Boots/Lloyds/Superdrug; E‑Prescriptions)

High‑Street And NHS Routes

Boots, LloydsPharmacy and Superdrug dispense prescriptions in the UK; finasteride remains prescription only so a valid prescription is required for supply.

MHRA licensing covers Propecia and generics.

Online Pharmacies And NHS E‑Prescriptions

Electronic prescriptions and reputable online pharmacy services can supply finasteride after a consultation; always verify GPhC registration and NHS integration.

Be cautious of unregulated overseas sellers where labelling and authenticity may differ; Finpecia is commonly manufactured by Cipla overseas.

• Check for the GPhC logo, requirement for a prescription and a contactable pharmacist when buying online.
• Inspect batch and expiry details on received packs.

In our online pharmacy, finpecia is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Mechanism & Pharmacology (Simplified + Clinical Terms)

Simplified Explanation

Finasteride inhibits 5α‑reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT).

Lower scalp DHT slows androgenetic hair loss and the same mechanism reduces prostate volume in BPH.

Clinical Terms And Codes

ATC codes are D11AX10 for hair loss use and G04CB01 for BPH.

Finasteride is hepatically metabolised and has a dosing schedule of once daily reflecting its pharmacology.

5α‑Reductase

The enzyme converting testosterone to DHT.

DHT

Dihydrotestosterone — the androgen implicated in hair follicle miniaturisation.

ATC Code

Classification system for active substances and indications.

POM

Prescription Only Medicine.

Indications & Off‑Label Uses (MHRA‑Approved + NHS/Private Practice)

MHRA‑Approved Uses

Approved indications are male androgenetic alopecia at 1 mg daily and BPH at 5 mg daily.

Finasteride is not approved for use in women or children.

Off‑Label Practices In NHS And Private Care

Off‑label approaches such as combining oral 5α‑reductase inhibitors with topical therapies or using dutasteride for hair loss occur more commonly in private practice and need informed consent.

• Off‑label might be considered in refractory cases after specialist referral.
• Document rationale, discuss risks and obtain written informed consent where appropriate.

Key Clinical Findings (UK/EU Evidence Summary 2022–2025)

Recent UK and EU reviews continue to support finasteride 1 mg for halting hair‑loss progression and improving hair count versus placebo.

For BPH, 5 mg reduces prostate volume and improves symptoms with benefits accruing over six months or more.

Safety data continue to reaffirm known sexual and mood adverse events, and pharmacovigilance is monitoring persistence in a minority.

Clinician note: balance efficacy timelines (3–6 months for hair, 6+ months for BPH) with informed consent about adverse‑event uncertainty.

Alternatives Matrix (NHS Alternatives And Pros/Cons)

NHS Prescribing Alternatives (Comparison Table)

Pros And Cons Checklist

• Pros: oral once daily dosing, evidence for efficacy in licensed indications, generics reduce cost.
• Cons: sexual side‑effects, pregnancy risk, need for long‑term continuous use to maintain hair benefits.
• Non‑pharmaceutical alternatives: hair concealers, cosmetic fibres, hair transplant referral for suitable candidates.

Common Questions From UK Consultations

Q1: How long before I see results?

• Expect hair stabilisation after three months and visible regrowth typically by six to twelve months; continue treatment to maintain results.

Q2: What are the common side‑effects?

• Reduced libido, erectile dysfunction, ejaculatory disorders, and sometimes mood changes or breast tenderness.
• Most are uncommon and often reversible, but persistent cases are reported.

Q3: Can women use it?

• No — not licensed and contraindicated in pregnancy; handling precautions apply for tablets.

Q4: Will it affect PSA testing?

• Yes — finasteride can lower PSA levels; clinicians should note baseline PSA and refer to urology guidance regarding adjusted thresholds.

NHS Cost & Access Comparison Table

This table is a ready template; update live prices before publication.

• Patients should check eligibility for free prescriptions and discuss private prescribing costs with their pharmacy or clinic.

Registration & Regulation (MHRA Approval, NHS Prescribing Framework)

MHRA Approval Process And Labelling

Finasteride products including Propecia 1 mg and Proscar 5 mg are MHRA‑licensed in the UK and classed as Prescription Only.

Product information details dosage, contraindications including pregnancy, storage and adverse effects.

NHS Prescribing Framework And Clinician Responsibilities

Prescribers should follow local formularies and document consent when prescribing finasteride.

Many NHS GPs will consider patient preference for hair loss and severity; private clinics may use off‑label options but must obtain informed consent and provide follow‑up.

• Check the MHRA Summary of Product Characteristics (SPC) before prescribing.
• Baseline PSA where indicated, counsel on fertility and pregnancy risks.
• Advise patients to report side‑effects to the MHRA Yellow Card scheme.

Storage & Handling (UK Household Guidance)

Storage And Transport

Store below 30°C in the original packaging, away from moisture and light.

Do not split or crush tablets because of exposure risk for pregnant women.

Keep out of reach of children.

UK Household Tips (Cold/Damp Climate)

Keep finasteride in a dry cupboard away from the bathroom or kitchen sink where humidity is high.

Check batch and expiry details and security seals when you receive the pack.

• Keep the medicine in its original pack.
• Avoid crushing tablets and do not handle crushed tablets if a pregnant woman may be exposed.
• Return unwanted or expired medicines to a pharmacy for safe disposal.
• Report missing or changed packaging to the supplier and pharmacist.

Guidelines For Proper Use: Pharmacist Counselling & NHS Patient Safety

UK Pharmacist Counselling Style

Pharmacists should confirm the indication and review contraindications such as pregnancy exposure risk and women/children.

Explain expected timelines (three months or more for hair) and common adverse effects and document the consultation.

For remote consultations ensure identity verification and adherence to GPhC standards.

NHS Patient Safety Advice

Advise patients to record any sexual or mood changes and to seek review if symptoms emerge.

If pregnancy exposure risk arises in a partner or household, stop handling tablets and seek urgent advice.

Report side‑effects through the MHRA Yellow Card scheme and offer referral pathways as needed.

• Counselling checklist: indication, dose, missed dose, storage, contraception/pregnancy warning, PSA implications and follow‑up timeline.
• Provide printed or online patient information and clear referral pathways to dermatology, urology or mental health services as appropriate.

Delivery Across United Kingdom